$BIIB Form 8-K

0
440

 

Form 8-K for BIOGEN INC.


3-May-2016

Regulation FD Disclosure, Financial Statements and Exhibits

Item 7.01 Regulation FD Disclosure.On May 3, 2016, Biogen announced that it intends to spin-off its hemophilia business through a distribution to stockholders of shares in a separate, publicly traded company. A copy of the press release announcing the proposed spin-off is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
Biogen will discuss the proposed spin-off in a live webcast to be held on May 3, 2016 at 8:30 a.m., Eastern Daylight Time. The webcast can be accessed through the Investors section of Biogen’s homepage, www.biogen.com. A copy of the presentation for the webcast is furnished as Exhibit 99.2 to this Current Report and is incorporated herein by reference.

Limitation on Incorporation by Reference. The information furnished in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.(d) Exhibits.
Exhibit Number Description
99.1 Biogen’s press release dated May 3, 2016.
99.2 Presentation for investors dated May 3, 2016.

LEAVE A REPLY

Please enter your comment!
Please enter your name here